Zacks: MeiraGTx Holdings PLC (MGTX) Given Consensus Recommendation of “Strong Buy” by Brokerages
MeiraGTx Holdings PLC (NASDAQ:MGTX) has received a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus price target of $22.33 for the company and are predicting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given MeiraGTx an industry rank of 112 out of 255 based on the ratings given to related companies.
Several brokerages recently commented on MGTX. Chardan Capital began coverage on shares of MeiraGTx in a research report on Thursday, August 23rd. They issued a “buy” rating for the company. Zacks Investment Research downgraded shares of MeiraGTx from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th. Evercore ISI began coverage on shares of MeiraGTx in a research report on Monday, July 9th. They issued an “outperform” rating and a $21.00 price target for the company. Barclays began coverage on shares of MeiraGTx in a research report on Tuesday, July 3rd. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Bank of America began coverage on shares of MeiraGTx in a research report on Tuesday, July 3rd. They issued a “buy” rating for the company.
Shares of NASDAQ:MGTX opened at $12.81 on Friday. MeiraGTx has a 52 week low of $7.98 and a 52 week high of $15.49.
MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($2.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($1.62). sell-side analysts forecast that MeiraGTx will post -4.17 EPS for the current fiscal year.
MeiraGTx Company Profile
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases.
Read More: Risk Tolerance and Your Investment Decisions
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.